Certain types of skin cancers and blindness due to age-related macular degeneration (AMD) and diabetic retinopathy are likely to be among the first uses for the drug. AMD is the most common cause of blindness in Australia (Macular Degeneration Foundation).
The experimental drug has already been shown to be effective on skin cancers in pre-clinical models, in another paper published this month by Professor Khachigian's team in the journal, Oncogene.
"This may be a 'one-size fits all' therapy, because it targets a master regulator gene called c-Jun which appears to be involved in all of these diseases," said UNSW Professor Levon Khachigian, of the Centre for Vascular Research (CVR), who is the senior author of the Nature Biotechnology paper.
"c-Jun is an important disease-causing gene," said Professor Khachigian, a molecular biologist. "It stands out because we don't see much of it in normal tissue but it is highly expressed in diseased blood vessels, eyes, lungs, joints, and in the gut – in any number of areas involving inflammation and aggressive vascular growth.
"Our experimental drug, Dz13, is like a secret agent that finds its target, c-Jun, within the cell and destroys it," he said. "It is a specific, pre-programmed 'molecular assassin'."
The paper in Nature Biotechnology shows the potential of c-Jun as a drug target in inflammation. It details tests in a variety of pre-clinical models showing how effective Dz13 is in problems such as eye disease and arthritis.
The next phase in the therapy's development would be a trial, involving up to 10 people with non-melanoma skin cancers. The tumours would be injected with the drug over an eight-week period.
"If such a trial were successful, it would be a significant development given the high rates of skin cancer and because the main treatment currently is surgical excision, which can cause scarring," said Professor Khachigian.
"Conventional anti-inflammatory drugs are associated with a whole host of side-effects. Our therapeutic may potentially avert some of these."
A third paper using the same technology, but focusing on a different master regulator, Egr-1, has also been published this month by Professor Khachigian's group in the Journal of Thrombosis and Haemostasis and shows that heart muscle damage is reduced by the drug after a heart attack.
Susi Hamilton | EurekAlert!
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences